Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented. Leishmania amazonensis is the second mo
BackgroundWith widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susc
aParasite counts (mean ± SD) were determined by luminometry in splenocytes isolated from hamsters at 21 days p.i. and cultured ex vivo with amphotericin B (AMB), 0.126 µg/mL or DMSO control for 48 h.b
